Neoadjuvant pamiparib plus abiraterone and androgen deprivation therapy for high-risk/very high-risk localized prostate cancer: an open-label, single-arm, phase 2 study.
Tangtao Gong, Shuo Liang, Zhigang Wu et al.
✦ AI-curated · Sources linked
In 30 seconds
This open-label, single-arm phase 2 study assessed four months of neoadjuvant pamiparib, abiraterone, and androgen deprivation therapy before prostatectomy in patients with high-risk or very high-risk localized prostate cancer. Of 30 enrolled patients, 29 completed treatment and underwent surgery. Eight patients (28%) achieved pathological complete response or minimal residual disease, including 3 (10%) with complete response and 5 (17%) with minimal residual disease. Surgical downstaging occurred in 18 patients (62%); two-year biochemical progression-free survival was 76%. No grade 3-4 treatment-related adverse events were reported.
Key findings
- Eight patients (28%) achieved pathological complete response or minimal residual disease: 3 (10%) and 5 (17%), respectively.
- Surgical downstaging occurred in 18 patients (62%), with no progression events reported.
- Two-year biochemical progression-free survival was 76%.
- No grade 3-4 treatment-related adverse events occurred; common grade 1-2 events included anemia (45%), elevated AST/ALT (34%), and hypertriglyceridemia (45%).
Why it matters
The findings provide early clinical evidence on a neoadjuvant combination targeting androgen receptor signalling and PARP in high-risk localized disease. Pathological response, downstaging, and reported tolerability are relevant outcomes before prostatectomy, while the observed two-year biochemical progression-free survival offers preliminary follow-up. The single-arm results are descriptive and do not establish benefit over other treatment approaches.
What to keep in mind
The study was single-arm and included 30 patients, so it cannot establish comparative efficacy; follow-up for the reported biochemical progression-free survival was two years.